EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation

Xiangru Tang iD, Howard Dai, Elizabeth Knight, Fang Wu, Yunyang Li, Tianxiao Li, Mark Gerstein iD

Briefings in Bioinformatics · 23.05.2024 · 25 (4)

DOI: 10.1093/bib/bbae338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 15.07.2024. Verfasst von Xiangru Tang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, Yale University, New Haven, CT 06520, United States. Hauptthemen laut MEDLINE: Artificial Intelligence, Drug Design, Proteins. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Schmidt Futures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artificial intelligence (AI)-driven methods can vastly improve the historically costly drug design process, with various generative models already in widespread use. Generative models for de novo drug design, in particular, focus on the creation of novel biological compounds entirely from scratch, representing a promising future direction. Rapid development in the field, combined with the inherent complexity of the drug design process, creates a difficult landscape for new researchers to enter. In this survey, we organize de novo drug design into two overarching themes: small molecule and protein generation. Within each theme, we identify a variety of subtasks and applications, highlighting important datasets, benchmarks, and model architectures and comparing the performance of top models. We take a broad approach to AI-driven drug design, allowing for both micro-level comparisons of various methods within each subtask and macro-level observations across different fields. We discuss parallel challenges and approaches between the two applications and highlight future directions for AI-driven de novo drug design as a whole. An organized repository of all covered sources is available at https://github.com/gersteinlab/GenAI4Drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceDrug DesignProteinsHumansComputational Biology

Stichwörter der Autor:innen

drug designgenerative modelmolecule generationprotein generation

Substanzen

Proteins

Autor:innen und Institutionen

  • Department of Computer Science, Yale University, New Haven, CT 06520, United States.
  • School of Medicine, Yale University, New Haven, CT 06520, United States.
  • Computer Science Department, Stanford University, CA 94305, United States.
  • Program in Computational Biology & Bioinformatics, Yale University, New Haven, CT 06520, United States.
  • Department of Statistics & Data Science, Yale University, New Haven, CT 06520, United States.
  • Department of Biomedical Informatics & Data Science, Yale University, New Haven, CT 06520, United States.

ORCID-Profile: Xiangru Tang, Mark Gerstein

Förderung

  • Schmidt Futures

Zitieren

APA

Tang, X., Dai, H., Knight, E., Wu, F., Li, Y., Li, T., & Gerstein, M. (2024). A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation. Briefings in Bioinformatics, 25(4). https://doi.org/10.1093/bib/bbae338

Vancouver

Tang X, Dai H, Knight E, Wu F, Li Y, Li T, et al. A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation. Briefings in Bioinformatics. 2024;25(4). doi:10.1093/bib/bbae338

BibTeX
@article{Tang2024,
  author = {Tang, Xiangru and Dai, Howard and Knight, Elizabeth and Wu, Fang and Li, Yunyang and Li, Tianxiao and Gerstein, Mark},
  title = {A survey of generative AI for de novo drug design: new frontiers in molecule and protein generation},
  journal = {Briefings in Bioinformatics},
  year = {2024},
  volume = {25},
  number = {4},
  doi = {10.1093/bib/bbae338}
}
Kostenlos starten →